<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10839289</article-id><article-id pub-id-type="pmc">2363227</article-id><article-id pub-id-type="pii">6691139</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.1139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matano</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tagliaferri</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Libroia</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Damiano</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fabbrocini</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>De Lorenzo</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bianco</surname><given-names>A R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare a Clinica, Facolt&#x000e0; di Medicina e Chirurgia, Universit&#x000e0; &#x0201c;Federico II&#x0201d;, Via S. Pansini 5, Napoli, 80131, Italy</aff><author-notes><fn fn-type="present-address" id="note1"><p>Present address: Dipartimento di Medicina Sperimentale e Clinica, Facolt&#x000e0; di Medicina e Chirurgia, Universit&#x000e0; &#x0201c;Magna Graecia&#x0201d;, Via T. Campanella 115, 88100 Catanzaro, Italy</p></fn></author-notes><pub-date pub-type="ppub"><month>06</month><year>2000</year></pub-date><volume>82</volume><issue>11</issue><fpage>1772</fpage><lpage>1775</lpage><history><date date-type="received"><day>16</day><month>04</month><year>1999</year></date><date date-type="rev-recd"><day>09</day><month>11</month><year>1999</year></date><date date-type="accepted"><day>22</day><month>12</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Gemcitabine and 5-fluorouracil are the only two compounds with reproducible activity against advanced pancreatic cancer (APC). We have evaluated a novel combination of gemcitabine and 5-fluorouracil on the clinical benefit response (CBR) end point. Eleven consecutive patients with symptomatic APC were entered in a two-stage phase II trial. Gemcitabine was administered by intravenous (i.v.) bolus injection at the dose of 1000 mg m<sup>&#x02212;2</sup>on days 1, 8, 15 and 5-fluorouracil 500 mg m<sup>&#x02212;2</sup>was given by continuous i.v. infusion on days 1&#x02013;5. Treatment was repeated every 28 days. A CBR was achieved in 7/11 patients. The mean time to loss of CBR was 26.5 weeks (range 14&#x02013;18, median 22). Toxicity was mild and no APC patient experienced WHO grade 3 toxicity. The gemcitabine/5-fluorouracil combination is well tolerated and produces a symptomatic relief in the majority of APC patients. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>advanced pancreatic cancer</kwd><kwd>phase II study</kwd><kwd>gemcitabine</kwd><kwd>5-fluorouracil</kwd><kwd>clinical benefit response</kwd></kwd-group></article-meta></front></article>


